Mice with NSCLC tumors ranging between 60 and 80 mm3 in size were administered anti-CD47 Ab (at a dosage of 10 mg/kg thrice/week), anti-CTLA4 Ab (at a dosage of 10 mg/kg thrice/week, or a combination of both. This evidence concerns the gene CD47 and non-small cell lung carcinoma.